Status: Not yet recruiting
Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases
This study is a single-arm, intervention, dose-escalation clinical trial to evaluate the safety of allogeneic CD19/BCMA-targeted CAR-γδT cell in the treatment of relapsed/refractory autoimmune diseases
Participants needed: 9
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Institute of Hematology & Blood Diseases Hospital, ChinaUpdated: Jun 9, 2026
Eligibility criteria
Age ≥18 years (including 18 years), no gender restrictions. [+32]
-Individuals with a history of severe drug allergies or an allergic constitution... [+12]